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Abstract
Background: In this work, the in vitro and in vivo stabilities and the pharmacology of HPMA-made homopolymers
were studied by means of radiometal-labeled derivatives. Aiming to identify the fewer amount and the optimal
DOTA-linker structure that provides quantitative labeling yields, diverse DOTA-linker systems were conjugated in
different amounts to HPMA homopolymers to coordinate trivalent radiometals Me(III)* = gallium-68, scandium-44,
and lutetium-177.
Results: Short linkers and as low as 1.6% DOTA were enough to obtain labeling yields > 90%. Alkoxy linkers
generally exhibited lower labeling yields than alkane analogues despite of similar chain length and DOTA incorporation
rate. High stability of the radiolabel in all examined solutions was observed for all conjugates. Labeling with scandium-44
allowed for in vivo PET imaging and ex vivo measurements of organ distribution for up to 24 h.
Conclusions: This study confirms the principle applicability of DOTA-HPMA conjugates for labeling with different
trivalent metallic radionuclides allowing for diagnosis and therapy.
Keywords: DOTA-HPMA conjugates, Theranostic, Radiolabeling, Gallium-68, Scandium-44, Lutetium-177, PET,
Biodistribution
Background
One of the major problems in current chemotherapy is
the lack of selectivity of the utilized anticancer drugs.
Conventional chemotherapeutic drugs suffer from a nar-
row therapeutic index as a consequence of affecting not
only cancer cells but basically all cells with high prolifer-
ation rates. The therapeutic index of a drug can be im-
proved by increasing the accumulation at the target site,
e.g., the tumor [1, 2]. Nanomaterials (< 100 nm) can
often improve pharmacokinetics due to their particle
size, charge, and shape and may passively and/or ac-
tively accumulate in tumor tissue. Since the early
1970s, N-(2-hydroxypropyl)methacrylamide (HPMA) is
investigated as drug delivery system based on the
enhanced permeability and retention (EPR) effect [3–5].
HPMA-based copolymers are hydrophilic, biocompat-
ible, and non-immunogenic [6, 7], and selection as drug
carrier is based on detailed studies of the relationship
between structure and biocompatibility of hydrophilic
polymers [8–13]. HPMA-copolymer conjugates have
been successfully utilized in the delivery of miscellaneous
drugs (e.g., doxorubicin [14], paclitaxel [15], camptothecin
[16]). Modification can be achieved through activated co-
monomers leading to biocompatible polymers with func-
tionalities for polymer analogue reaction. This strategy is
very flexible in the choice of ligands, type of activation,
and occupancy rate and was already used in various
studies [17].
As it was shown before, nanomaterials like HPMA-
based nanocarriers are able to combine both imaging
agents and drugs within one formulation [8, 18, 19] for
the in vivo analysis by positron emission tomography
(PET) [20, 21]. Those studies include information about
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the early pharmacology of fluorine-18-radiolabelled HPMA
derivatives, yielding information of excretion pathways,
blood retention, and organ distribution. According to the
physical half-life of fluorine-18 of 110 min, those data only
cover a period of 2 to 4 h post injection. For an investiga-
tion of later time points, in particular when drug accumu-
lation in tumors is of interest, radionuclides of longer
physical half-life are needed. Here, we intent to introduce a
radiolabeling concept based on a chelator being (i) ad-
equate to the coordination chemistry of trivalent metals,
namely DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid), and being (ii) covalently attachable to the
HPMA structure.
Two generator-produced positron emitters of choice
are gallium-68 and scandium-44, which can be applied
to quantitative in vivo imaging via PET. Gallium-68 is a
positron emitter (89%) with a half-life of 67.71 min and
average positron energy of 1.899 MeV. Its physical half-
life is adequate to allow the preparation and purification
of gallium-68-labeled radiopharmaceuticals and for im-
aging biological processes with short half-life. The major
advantage of gallium-68 is its availability via a 68Ge/
68Ga-generator system, which provides a cyclotron-
independent and cost-effective source of the isotope in
suitable conditions for labeling after its post-processing
[22–27]. Scandium-44 (94% positron emission) is avail-
able via the 44Ti/44Sc-generator system [28, 29]. Due to
its longer physical half-life of 3.97 h, scandium-44 facili-
tates the tracking of processes with longer biological
half-life than gallium-68 or even fluorine-18. It could be
applied for more exact planning and dosimetry calcula-
tions in endoradiotherapy [27]. In addition, longer-lived
lutetium-177 (6.7 days) can be used as well for ex vivo
organ distribution studies. Lutetium-177 is not suitable
for PET imaging, but as a result of emitting gamma radi-
ation (113.0 and 208.4 keV) in addition to its β− parti-
cles, it can be used for therapy and SPECT imaging [30].
Those radiolabeled HPMA derivatives appear also to be
suitable to investigate processes such as the EPR-
mediated accumulation of nanoparticles in tumor tissue.
In addition, HPMA polymers could also be labeled
with iodine-123 [31] to visualize tumors and metastases
by SPECT or 99m-technetium [32] as it was done be-
fore. To our knowledge so far, no studies exist with
iodine-124-labeled HPMA polymers but this radio-
nuclide was already used to enable long-term tumor
PET imaging of clinically approved silica nanoparticles
[33] and could also be a useful tool for imaging long-
circulating HPMA polymers.
In the present study, we aimed to synthesize DOTA-
conjugated HPMA homopolymers with alkyl- and alkoxy
linkers for labeling with trivalent metallic radionuclides.
The main objective was to show how the linker (in
terms of structure and length) as well as the amount of
incorporated DOTA may influence labeling kinetics, sta-
bility, and whether labeling procedures for different ra-
dionuclides can be utilized. Labeling of the synthesized
DOTA-conjugated homopolymers was first performed
with gallium-68 to evaluate reaction parameters (incuba-
tion time, amount of compound, temperature, influence
of organic solvent). The stability of the gallium-68-
labeled conjugates was analyzed in vitro in 0.9% NaCl
and human serum albumin (HSA), as well as in the
presence of different metal cations and other competing
chelators, like EDTA and DTPA. Additionally, labeling
with the diagnostic and therapeutic isotopes scandium-
44 and lutetium-177 was performed to allow for the
characterization of late organ distribution profiles of the
HPMA-based nanoparticles in following studies. Proof
of principle in vivo distribution was investigated by PET
with a HPMA-DOTA conjugate of 13 kDa, a short ethyl
linker, and a low DOTA/HPMA ratio (1.6%), which was
radiolabeled with scandium-44.
Methods
All chemicals were analytical or pure reagent grade and
used as received unless otherwise specified. DOTA-
(tBu)3 was obtained from CheMatech (Dijon, France).
All other organic and inorganic reagents were purchased
from Sigma-Aldrich (Munich, Germany) and Across Or-
ganics (Geel, Belgium). Deionized Milli-Q water
(18.2 MΩ cm; Millipore, Darmstadt, Germany) was used
in all organic reactions. Dioxane was distilled over a so-
dium/potassium composition. Lauryl methacrylate was
distilled to remove the stabilizer and stored at − 18 °C.
2,2′-Azo-bis-(isobutyronitrile) (AIBN) was recrystallized
from diethyl ether and stored at − 18 °C as well. 1H-
NMR spectra were obtained by a Bruker AC 300 spec-
trometer (Bruker, Karlsruhe, Germany) at 300 MHz. The
amount of incorporated DOTA derivatives 17–21 in the
polymers was determined by inverse gated 13C-NMR.
19F-NMR analysis was carried out with a Bruker DRX-
400 at 400 MHz. It proved the complete conversion of
the reactive ester units by reaction with the DOTA de-
rivatives and 2-hydroxy-propylamine in analogy to [34].
The synthesized polymers were dried at 40 °C under
vacuum overnight, followed by gel permeation chroma-
tography (GPC). GPC was performed in tetrahydrofuran
(THF) as solvent, using the following equipment: pump
PU 1580, autosampler AS 1555, UV detector UV 1575,
and RI detector RI 1530 from Jasco (Pfungstadt, Germany)
as well as a miniDAWN Tristar light scattering detector
from Wyatt (Dernbach, Germany). Columns were used
from MZ Analysentechnik, 300 × 8.0 mm: MZ-Gel SDplus
106 Å 5 μm, MZ-Gel SDplus 104 Å 5 μm, and MZ-Gel
SDplus 102 Å 5 μm. GPC data were evaluated by using the
software PSS WinGPC Unity (Polymer Standard Service
Mainz, Germany). The flow rate was set to 1 mL/min with
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a temperature of 25 °C. Commercial 68Ge/68Ga generators
based on TiO2 phase absorbing
68Ge(IV) were obtained
from Cyclotron Co., Ltd. (Obninsk, Russia). Typically,
batch activities of 80–150 MBq were used. Scandium-44
was provided from a 44Ti/44Sc-generator system developed
in Mainz [28]. Batch activities of 165–180 MBq were used.
Lutetium-177 was obtained from ITG (Munich, Germany)
and used without further purification. Counting was per-
formed in a borehole counter (Nuklear-Medizintechnik
Dresden GmbH, Germany). Thin-layer chromatography
(TLC) was performed on silica-gel (silica-gel 60F254;
MERCK, Darmstadt, Germany)-coated aluminum TLC
sheets and analyzed using an instant imager (Instant
Imager, Canberra Packard, Schwadorf, Austria). The cation
exchange resins AG 50W-X8 (− 400 mesh), AG 50W-X4
(200–400 mesh), and AG 50 W–X8 (200–400 mesh) were
obtained from Bio-Rad (Munich, Germany). Strata-X
mini-C-18 cartridges were obtained from Phenomenex
(Aschaffenburg, Germany). HiTrap™ Desalting Columns
were purchased from GE-Healthcare Europe GmbH
(Freiburg, Germany). TraceSelect water (Sigma-Aldrich,
Germany) was used for all aqueous radiolabeling solutions.
Synthesis and characterization of DOTA-HPMA conjugates
The DOTA-HPMA conjugates were prepared following
the synthesis routes depicted in Figs. 1 and 2. Figure 1
shows the preparation of different DOTA linkers that
later on were conjugated to the HPMA backbones in dif-
ferent amounts. Details on the synthesis route and
characterization are added in the supplementary infor-
mation. The hydrodynamic radius (Rh) of the polymers
(0.1 mg/ml in isotonic NaCl solution) was determined
by Fluorescence Correlation Spectroscopy (FCS) at RT.
Radiochemistry
Labeling with gallium-68 Labeling of DOTA-conjugated
HPMA homopolymers was performed by mixing aliquots
of polymer stock solution (1 mg/mL in water) with post-
processed gallium-68 eluate [24, 25]. Investigation of the
amount of conjugate needed for labeling reaction was
performed by varying time and concentration of DOTA-
conjugated polymer using conjugate 31 with acetone post-
processed gallium-68 and was adopted for all the other la-
beling reactions. In addition, labeling with HPMA homo-
polymer without DOTA functionalization was performed
under these conditions to investigate the unspecific bind-
ing. Reaction mixtures were heated up to 95 °C for 30 min.
Labeling with scandium-44 Labeling of DOTA-
conjugated HPMA homopolymers was performed
with 250 μL polymer stock solution (1 mg/mL in
water) in post-processed scandium-44 eluate (3 mL)
and heating up to 95 °C for 30 min [35].
Labeling with lutetium-177 Labeling of DOTA-
conjugated HPMA homopolymers was performed with
250 μL polymer stock solution (1 mg/mL in water) with
150 μL 0.1 M Na acetate buffer (pH = 8) and 100 μL
lutetium-177 and heating up to 95 °C for 30 min. The
stoichiometric ratio polymer-to-lutetium-177 was 10:1.
Purification of the labeled conjugates The radiola-
beled polymeric systems were cleaned from unreacted
radiometal by Sephadex G-25 size exclusion chromatog-
raphy (HiTrap™ Desalting Column, Sephadex G-25
Superfine, 0.9% NaCl, flow rate: 0.5 mL/min) leading to
a pure, gallium-68-labeled polymer solution ready for
subsequent experiments.
Quality control Quality control of complex formation
was performed by radio thin-layer chromatography
(radio-TLC). The TLC plates were developed with
0.1 M citric buffer (pH = 4). Quantitative distribution of
radioactivity on TLC plates was measured using an in-
stant imager.
Stability of the labeled compounds Stability studies
were performed with gallium-68-labeled polymers of
radiochemical purity > 98% in physiological conditions
and in the presence of competing metals and chelates.
Fig. 1 Synthesis of the (tBu)3-DOTA linkers (17–21)
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Detailed setup is explained in the supplementary section.
As nonspecific binding of the metal cation to nanoparti-
cles is a basic problem in labeling those systems, investi-
gation of nonspecific binding of gallium-68 to a HPMA
polymer was performed with 20 nmol HPMA homopoly-
mer without functionalization (Mn: 12.000 g/mol, 0%
DOTA) utilizing the optimized protocol.
In vivo PET imaging and ex vivo biodistribution
Six–8-week-old male C57BL/6J (Janvier, France) mice
were housed under specific pathogen-free conditions in
the animal care facility in Mainz according to the guide-
lines of the regional animal care committee. All experi-
ments were performed in accordance with federal
guidelines and approved by the ethical committee of the
state of Rheinland-Pfalz (according to §8 Abs. 1
Tierschutzgesetz, Landesuntersuchungsamt; permission
no. 23177-07/G121-092 to M. Miederer). All injections
and imaging experiments were done under isoflurane
anesthesia to minimize suffering. Mice were injected
subcutaneously with 2 × 105 murine B16-F10 melanoma
tumor cells into the right flank. When tumors reached a
volume of 150–200 mm3, 44Sc-labeled polymer conju-
gate 31c (1.5 mg in 1 mL of isotonic saline) was injected
i.v. in anesthetized mice with a mean activity of 4.6 ±
0.5 MBq. Whole body scandium-44 PET scans were dy-
namically acquired over 120 min post injection (p.i.), or
30-min static scans were performed 90 min, 210 min,
and 24 h p.i.
All PET imaging studies were performed on a
nanoScan PET/MRI (Mediso, Budapest, Hungary), and
PET data were dynamically reconstructed with Tera-
tomo 3D (4 iterations, 6 subsets, voxel size 0.4 mm)
using user defined frames (3 × 20; 3 × 60; 3 × 120; 10 ×
300; 6 × 600 s) or statically using one 30-min frame.
Afterwards, the PET images were analyzed with pmod
software (version 3.6).
After 2, 4, and 24 h, the animals were sacrificed and
different organs and blood were removed. The tissue
samples were weighed and the 44Sc activity in the organs
was directly measured in a γ-counter (2470 WIZARD2
Automatic Gamma Counter, PerkinElmer) to calculate
the percentage of accumulated activity as % ID/g.
Ex vivo metabolism evaluation
Blood samples (ca. 100 μl), collected during the biodis-
tribution, were mixed with heparin solution (150 μl) to
avoid coagulation. Blood samples were weighed and ac-
tivity was measured in a γ-counter; 500 μl of PBS were
added and the blood was centrifuged at 1700×g for
3 min in order to separate blood cells and plasma. The
plasma fractions were weighed and activity was mea-
sured in a γ-counter. Proteins and polymers were pre-
cipitated by adding the same volume of acetonitrile to
the plasma fraction. To separate proteins and polymer
from plasma water, the samples were centrifuged at
1700×g for 3 min. The supernatants were weighed
followed by determination of the activity in a γ-counter.
The percentage of radioactivity in the blood cells, pro-
tein plus polymers, and plasma water fractions was cal-
culated by subtracting the activities of the supernatants
from the activity of the whole blood sample.
Results
Organic synthesis
For coupling reaction between the HPMA backbone and
the bifunctional chelator, orthogonal amidation chemis-
try via active ester groups was selected [17]. Synthesis
of the amine-terminated DOTA-based ligands 17–21
from commercially available (tBu)3-DOTA is depicted
in Fig. 1.
First, the commercially available α,ω-diamines 1–5
were mono-Cbz-protected. The protection was realized
with benzylphenylcarbonate 6 for 1–3 (Additional file 1)
Fig. 2 Synthesis of the HPMA-linker-DOTA systems (31–35)
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and with benzylchloroformate for 4–5. The selectivity of
the mono-Cbz-protection using 6 decreases with the
length of the alkyl chain but achieves good yields for 1–3.
Mono-Cbz-protection with 6 was ineffective for the alk-
oxy diamines 4–5 so benzylchloroformate was used in-
stead obtaining good yields of the desired product. The
following amidation of (tBu)3-DOTA with 7–11 afforded
the Cbz-protected (tBu)3-DOTA ligands 12–16 in good
yields of 66–79%. The Cbz-protecting group was removed
via hydrogenation to obtain the (tBu)3-DOTA ligands
17–21 in almost quantitative yields (93–97%).
The synthetic route to the DOTA-HPMA conjugates
is depicted in Fig. 2. Starting from pentafluorophenyl meth-
acrylate monomer 23, the precursor homopolymer 24 was
synthesized according to literature (Additional file 1). The
dithioester end group was removed by an excess of
2,2′-azo-bis-(isobutyronitrile) as described in literature
(Additional file 1) taking the advantage of circumvent-
ing side reactions during the next reaction steps. Func-
tionalization of the polymeric precursor was obtained
by aminolysis via the amine-terminated (tBu)3-DOTA li-
gands 17–21. The incorporation was calculated to be be-
tween 0.6–11% DOTA for each conjugate by inverse gated
13C-NMR spectroscopy. Addition of 2-hydroxypropylamine
leads to the polymeric structures 26–30. The entire conver-
sion of the reactive ester groups was proved by means of
19F-NMR spectroscopy, which demonstrates complete dis-
appearance of 19F signals of the polymeric backbone in ana-
logy to [34]. As these reactions were performed in water-
free conditions, they happen without side reactions [34]. In
a final step, the chelator was deprotected using TFA. The
pure HPMA-DOTA conjugates, ready for labeling, could
be obtained as white powders with good yields of 89%, ex-
cept conjugate 32, which could not be recovered from the
dialysis flexible tube.
As intended, five different DOTA-conjugated polymer
conjugates with relatively low polydispersity index (PDI)
and narrow molecular weight distribution (Rh: 1.3–
1.5 nm) have been achieved by RAFT polymerization
and successfully functionalized in a following polymer
analogous reaction. Their molecular weight average
numbers (Mn), polydispersity indices (PDI), and % of in-
corporated chelators are shown in Table 1.
Later on, in order to have only one variable for direct
comparison (the conjugates so far presented different
linker structures with different incorporation rates of
DOTA), conjugate 31 was modified with different per-
centages of DOTA, affording the conjugates 31a–31c
following the same synthesis route as described for con-
jugate 31 (Table 2).
Radiochemistry
DOTA derivatives generally require elevated temperatures
for complex formation in contrast to acyclic chelators;
95 °C was used as standard temperature for labeling ex-
periments with the DOTA-HPMA conjugates with differ-
ent radionuclides (e.g., gallium-68, scandium-44, lutetium-
177). Figure 3 shows the kinetics of [68Ga]Ga-31 complex-
ation depending on the amount of the DOTA-HPMA 31
ranging from 12 to 36 nmol. The accessible labeling yield
is not influenced by the amount of conjugate used. Only
12 nmol showed a slightly lower labeling yield. Thereon,
in order to work with the fewest amount of polymer while
achieving maximal labeling yield in a short time, 20 nmol
was used for further experiments. Labeling with
generator-derived and acetone post-processed gallium-68
in water is accomplished within 15 min at 95 °C with RCY
of 90%. The complex formation is fast and efficient. In-
vestigation of nonspecific binding of gallium-68 to a
HPMA polymer was performed with 20 nmol HPMA
homopolymer without DOTA functionalization. Within
25 min, less than 5% of the radioactivity binds to the
HPMA homopolymer (Fig. 3).
Next, it was tested if the radiolabeling yields are influ-
enced by the DOTA incorporation rate in polymers with
the same linker length (Fig. 4). It can be observed that
radiolabeling kinetics is not directly proportional to the
amount of incorporated chelator. The fastest radiolabel-
ing kinetics are shown for conjugate 31a with 4.8%
DOTA. Slower kinetics are achieved for conjugate 31
with 11% DOTA and slightly slower radiolabeling kinetics
for the polymer with 1.6% and with 3.3% of incorporated
DOTA. After 25 min, all conjugates reach the same
labeling yield and do not show further differences.
Table 1 Analytical data of the final HPMA-DOTA conjugates
31–35
Polymer Mn [g/mol] PDIa % DOTAb Linker
31 15.000 1.3 11 (1)
33 12.000 1.2 1.6 (3)
34a 12.000 1.2 0.6 (4)
34b 12.000 1.2 1.2 (4)
35 13.000 1.2 3.5 (5)
aDetermined by GPC in THF as solvent
bDetermined by 1H-NMR spectroscopy after polymer analogous reaction
with 2-hydroxypropylamine
Table 2 Analytical data of the final HPMA-DOTA conjugates
(derivatives of type 31)
Polymer Mn [g/mol] PDIa % DOTAb Linker
31 15.000 1.2 11 (1)
31a 14.000 1.2 4.8 (1)
31b 13.000 1.2 3.3 (1)
31c 13.000 1.2 1.6 (1)
aDetermined by GPC in THF as solvent
bDetermined by 1H-NMR spectroscopy after polymer analogous reaction
with 2-hydroxypropylamine
Eppard et al. EJNMMI Research  (2018) 8:16 Page 5 of 14
One could hypothesize that labeling efficiency will be
related to linker length and linker structure. To test this,
DOTA-HPMA conjugates 31, 33, 34a/b, and 35 were la-
beled using the same conditions as before. Within
15 min, labeling yields of 44–92% can be achieved (Fig. 5,
Table 3). The highest labelling yields can be found for
conjugate 31 with the shortest alkyl linker (91%) and
highest DOTA content (11%) followed by conjugate 33
with the longest alkyl linker (75%) and 10-fold lower
DOTA content (1.6%). This shows that labeling yield is
affected by the length of the linker as well as the DOTA
content. Furthermore, all conjugates with alkoxy linkers
showed distinct lower radiolabeling yields compared to
those with alkyl linkers whereupon conjugate 34b shows
slightly higher labelling yield than conjugate 35 with the
longer alkoxy linker showing again the influence of the
linker length. Conjugate 34a with a very low DOTA con-
tent (0.6%) shows almost no labeling.
Recently, the benefit of additional use of organic sol-
vents to facilitate radiolabeling was proven [36] and uti-
lized in an ethanol-based post-processing. It has been
shown that this ethanol-based post-processing protocol
significantly increases radiochemical yields even at lower
temperature compared to the standard procedure for
DOTATOC as model compound [26]. To take the ad-
vantage of additional ethanol, enhancing labeling yields,
Fig. 3 Time course of 68Ga-complex formation with varying amounts of DOTA-HPMA conjugate 31 and polymer (20 nmol) not modified with
DOTA as a control
Fig. 4 Radiolabeling yield of conjugates 31 with different amounts of DOTA utilizing acetone post-processed gallium-68 (20 nmol; 25 min; 95 °C; n= 3)
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conjugates 33–35 were labeled utilizing this protocol
too. Additional file 1: Figure S1 shows the results of la-
beling conjugate 33 utilizing the two post-processing
methods. Labeling with the ethanol post-processed
gallium-68 in 1 M NaHEPES buffer leads to significantly
increased yields of complex formation. The difference
between both labeling procedures is accounted for 20%. An
additional advantage of the ethanol-based post-processing
is the possibility to reduce the overall volume of the labeling
solution from 5.25 mL (acetone) to 2.25 mL (ethanol), and
therefore to increase the specific activities.
This shows that labeling is also affected by the linker
structure. Conjugates 33 and 35 have the same chain
length (n = 11) but differ in their structure. Conjugate 33
contains a dodecyl linker while the positions 4 and 9 are
substituted with oxygen atoms in the linker chain of 35.
This structural difference is reflected in the decreasing
labeling yield from 75% 33 to 45% 35.
Purification of gallium-68-labeled DOTA-HPMA conjugates
and quality control
After labeling, the polymeric systems could be purified
fast and easy using Sephadex G-25 size exclusion chro-
matography. Over 90% of the radiolabeled product can
be collected in two fractions with radiochemical purity
of > 98%. As the product is eluted from the column with
0.9% NaCl, the resulting solution could be directly used
for in vivo studies. Radiochemical analysis of complex
formation was performed by TLC. The Rf values for free
uncomplexed gallium-68 and labeled conjugates were
determined as Rf ([
68Ga]Ga3+) = 0.9 and Rf (
68Ga conju-
gate) = 0. The Rf values for scandium-44 and lutetium-
177 utilizing the same method are the same as for
gallium-68, 0.9.
Radiolabeling with scandium-44
As conjugate 31 showed the best radiolabeling yield, this
conjugate was used for further labeling experiments with
scandium-44 and lutetium-177. Scandium belongs to the
transition metal group, and its complex formation strongly
depends on pH of aqueous solution as previously shown
for [44Sc]Sc-DOTATOC complex formation [35]. Utilizing
the post-processing method leads to a final solution of
scandium-44 in ammonium acetate buffer (pH 4) suitable
for direct labelling [29]. Labeling with post-processed
scandium-44 in ammonium acetate buffer (pH 4) yields up
to 95% within 30 min for DOTA-HPMA 31 (Fig. 6).
Radiolabeling with lutetium-177
Radiolabeling with lutetium-177 is fast and efficient. Within
3 min, reaction is completed and yields up to 97% can be
obtained for DOTA-conjugated HPMA 31 (Fig. 6).
Stability of labeled compounds
Stability of the formed complex is a crucial factor in the
development of new radiopharmaceuticals. Therefore,
several experiments were done to explore stability of the
labeled conjugates in NaCl (used as final solvent),
Fig. 5 Labeling yield using acetone post-processed gallium-68 (20 nmol; 15 min; 95 °C; n = 3)
Table 3 Labeling of HPMA-DOTA conjugates 31–35 using
acetone and ethanol post-processed 68Ga eluate (20 nmol,
20 min, 95 °C)
Polymer Linker % DOTA RCY acetone PP (%) RCY ethanol PP (%)
31 (1) 11 91 ± 1 98 ± 1
33 (3) 1.6 75 ± 2 97 ± 1
34a (4) 0.6 2 ± 1 25 ± 8
34b (4) 1.2 55 ± 3 40 ± 8
35 (5) 3.5 45 ± 22 67 ± 6
Eppard et al. EJNMMI Research  (2018) 8:16 Page 7 of 14
Fig. 6 Labeling yields for 31 with scandium-44, gallium-68, and lutetium-177 (20 nmol; 30 min; 95 °C; n = 3)
Fig. 7 Stability of gallium-68-labeled conjugates in 0.9% NaCl (a) and in HSA (b) within 120 min at 37 °C (n = 3)
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human serum albumin, against trans-metalation (Fe3+;
Ca2+; Mg2+) and trans-chelation (EDTA, DTPA).
Stability of gallium-68-labeled DOTA-HPMA conju-
gates in 0.9% NaCl is presented in Fig. 7a. It indicates a
high stability of the labeled conjugates even after 2-h in-
cubation at 37 °C.
In human serum albumin, the conjugates with alkyl
linkers 31 and 33 indicate high stability. For both conju-
gates, the percentage of intact gallium-68 conjugate is
higher than 95%. Contrary to that, the conjugates with
alkoxy linker structure show higher decomposition rate
(Fig. 7b).
The presence of different metal cations (e.g., Fe3+) in
the final solution or in the blood can cause trans-
metalation of the radiolabeled conjugate and finally lead
to a release of free radionuclide into solution. Therefore,
it is necessary to determine whether the conjugate forms
stable complexes in the presence of relevant metal cat-
ions or not prior to in vivo studies.
Conjugate 31c shows the highest stability against
trans-metalation (Table 4). Similar to studies of 34–35
in HSA, stabilities are affected by addition of other metal
cations. Within 120 min, decomposition up to 30% can
be observed. More complex are the results for 33. This
conjugate indicates high stability in experiments with
HSA, Fe3+, and Ca2+ while decomposition is observed
for challenge studies against Mg2+.
Similarly, stability against other complexing agents like
EDTA and DTPA was investigated to check if trans-
metalation from HPMA-DOTA conjugate to competing
ligand occurs. The results are shown in Table 5. Here,
conjugates 34a and 34b show trans-metalation to DTPA
with more than 30%. All other conjugates are relatively
stable to both agents.
Furthermore, one polymer (31c) was labeled with
scandium-44 as described in Section 3.2.2, and its stabil-
ity was evaluated in 0.9% NaCl and HSA for up to 24 h
at 37 °C in order to use this polymer for downstream in
vivo applications. Table 6 shows that the 44Sc-labeled
polymer is very stable over a time period of up to 24 h
with values > 94% in NaCl and HSA.
In vivo and ex vivo biodistribution
For the biological evaluation, 44Sc-labeled derivatives were
considered in order to demonstrate that the use of triva-
lent radiometals is favorable in extending the time period
of molecular PET imaging compared to 18F-labeled ana-
logues without changing the pharmacokinetics. Because of
the minimal alterations to structure and geometry and
very good radiochemical purity and stability (Table 6), the
44Sc-labeled DOTA-HPMA polymer 31c with the lowest
DOTA incorporation and a short alkyl linker was chosen
and evaluated in B16 tumor-bearing mice. The dynamic
PET acquisition over a time course of 2 h p.i. shows a fast
renal excretion of the tracer (Fig. 8a) due to the low mo-
lecular weight of the HPMA homopolymer. The heart still
shows a robust signal 2 h p.i. while the tumor hardly gets
visible over time.
The pharmacokinetics over 24 h shows a relatively low
but constant tumor uptake over 4 h and is still visible
after 24 h (Fig. 8b) while the uptake in heart declines.
The coronal slices show that the tracer mainly accumu-
lates in the outer rim of the tumor after 4 and 24 h. This
hints at a poor vascularization inside the tumor what
could also be observed during the dissection of the
tumors.
These results are supported by the ex vivo evaluation of
the different tissues (Fig. 9, Additional file 1: Table S1).
A fast clearance through the kidneys is observed after
2 h with values of 32.9 ± 6.6% ID/g (urine: 54.6 ± 9.2%
ID/g) staying constantly over time. After 24 h, the activ-
ity in urine dropped to 32.4 ± 10.2% ID/g.
Uptake in the lungs, liver, and heart remained consid-
erably constant during the three time points studied
Table 4 Stability of gallium-68 conjugates at 37 °C in the presence
of different metal cations at 10− 2 M concentrations (n= 3)
Conjugate Linker % DOTA % of intact 68Ga conjugate ± SD
Fe3+ Mg2+ Ca2+
31c (1) 1.6 94 ± 3 92 ± 1 92 ± 5
33 (3) 1.6 94 ± 9 69 ± 2 99 ± 2
34a (4) 0.6 88 ± 2 80 ± 3 70 ± 1
34b (4) 1.2 84 ± 2 86 ± 2 90 ± 1
35 (5) 3.5 74 ± 2 85 ± 1 83 ± 8
Table 5 Stability of 68Ga conjugates at 37 °C in the presence of
EDTA or DTPA at molar ratio 100:1 of competing ligand to
conjugate (n = 3) after 120 min
Conjugate Linker % DOTA % of intact 68Ga conjugate ± SD
EDTA DTPA
31c (1) 1.6 92 ± 5 83 ± 1
33 (3) 1.6 90 ± 2 87 ± 1
34a (4) 0.6 77 ± 2 59 ± 1
34b (4) 1.2 80 ± 3 61 ± 1
35 (5) 3.5 78 ± 5 93 ± 1
Table 6 Stability of 44Sc conjugate 31c at 37 °C in 0.9% NaCl
and HSA during 24 h (n = 3)
Time (h) % of intact 44Sc conjugate ± SD
0.9% NaCl HSA
1 98.7 ± 0.5 96.7 ± 0.9
4 98.3 ± 0.9 95.7 ± 0.5
24 97.7 ± 0.5 94.3 ± 0.5
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Fig. 8 a In vivo dynamic PET of [44Sc]Sc-DOTA-HPMA 31c in a tumor-bearing mouse (n = 1). Maximum intensity projections (MIPs) of different
time points during 2-h acquisition. b Representative static PET images of [44Sc]Sc-DOTA-HPMA 31c in tumor-bearing mice 2, 4, and 24 h p.i. (the
last 30 min is imaged). Coronal and axial slices are shown with focus on tumor
Fig. 9 Ex vivo biodistribution of [44Sc]Sc-DOTA-HPMA 31c in tumor-bearing mice (n = 5 for each time point)
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with mean values of 5.6 ± 1.2, 4.2 ± 0.5, and 4.0 ± 0.5%
ID/g (mean values for each organ over time) respectively.
Uptake in the spleen increased after 24 h when compared
to the earlier time points. The tumor uptake after 2 h p.i.
was of 4.4 ± 0.8% ID/g and slightly increased to 5.1 ± 1.7%
ID/g after 4 h p.i. The blood values are comparable be-
tween 2 h (15.5 ± 1.8% ID/g) and 4 h p.i (16.6 ± 3.7%
ID/g). Interestingly, the tumor uptake further increases
after 24 h (to 8.2 ± 3.1% ID/g) while tracer concentra-
tion in the blood decreases (5.5 ± 1.5% ID/g).
Taken together, 44Sc-DOTA labeling of HPMA homo-
polymers is well suited for measuring the body distribu-
tion for a time period of up to 24 h in vivo and ex vivo.
Ex vivo metabolism
In order to investigate the in vivo stability of the labeled
polymer with scandium-44, the blood samples obtained
during biodistribution were separated into different frac-
tions: blood cells, polymer + proteins, and plasma water.
Figure 10 shows the amount of radioactivity in the dif-
ferent fractions with reference to the total amount of
radioactivity in the blood samples of 44Sc conjugate 31c.
The fraction containing proteins and protein-bound
polymer presents 55.2 ± 1.4% of total activity in blood
2 h p.i. This value remained stable after 4 and 24 h p.i.
with values of 49.8 ± 6.6% and 52.1 ± 6.3% respectively.
In the blood cell fractions, the activity also remained
constant during the three time points analyzed (values
ranged from 37.2 ± 2.2% to 40.1 ± 1.3%). Only a small
proportion of about 10% was found in the plasma water
comprising of free scandium-44 and maybe a small
amount of [44Sc]Sc-HPMA that could not be precipi-
tated completely indicating a good in vivo stability.
Discussion
Optimized conjugation of DOTA onto HPMA backbone
yielded several DOTA-linker-poly(HPMA) conjugates
with different linker structures and with variation of
amount of DOTA. These derivatives were labeled with
various metallic radionuclides (gallium-68, scandium-44,
lutetium-177). Labeling and stability of the produced con-
jugates were investigated in detail with the generator-
derived PET radionuclide gallium-68.
It was observed that labeling kinetics with gallium-68
slightly depend on the incorporation rate of DOTA.
There seems to be a kind of an optimum amount of
4.8% DOTA for a very fast labeling and at the same time
11% DOTA is too much to efficiently coordinate gallium
into the chelator and 1.6% DOTA is insufficient to quan-
titatively bind gallium, but after 25 min, no differences
between the various DOTA amounts were evident. This
shows that a minimum of 1.6% DOTA is enough to ob-
tain labeling yields higher than 90%. The linker structure
also is a variable that influences labeling efficiency. Alk-
oxy linker structure generally exhibits lower labeling
yields than alkane linkers despite of similar chain length
and DOTA incorporation. Moreover, it was observed
that a short linker (two-carbon chain) is enough to pro-
vide quantitative radiolabeling yields. Another investi-
gated effect is the radiolabeling in the presence of
ethanol, which is known to improve labeling efficacy.
Fig. 10 Distribution of [44Sc]Sc-31c in the blood for up to 24 h (n = 3). Data is expressed as percentage of the amount of radioactivity that was
present in the whole blood sample (mean ± SEM)
Eppard et al. EJNMMI Research  (2018) 8:16 Page 11 of 14
Utilizing the ethanol post-processed 68Ga eluate en-
hances the labeling efficacy for all conjugates. In conclu-
sion, ca. 1.6% of DOTA per HPMA polymer allow
achieving quantitative radiolabeling, if the optimal con-
ditions are applied.
With regard to future in vivo evaluations, special efforts
were focused on stability studies of 68Ga-labeled conju-
gates, to adopt the successful candidate to scandium-44
(PET imaging) and lutetium-177 (therapy). Only the con-
jugates with alkyl chains as linker structure provide high
stability in all examined solutions: 0.9% NaCl, HSA, metal
cations (Fe3+, Mg2+, Ca2+), and competing ligands (EDTA,
DTPA). In general, alkoxy linkers show lower labeling
yields and stability than alkyl linker conjugates irrespective
of DOTA content. Within the group of conjugates con-
taining alkyl linkers, DOTA content seems to have a mild
impact on labeling yield because there is a little difference
between the conjugate containing 11 and 1.6% DOTA. In
the conjugates containing alkoxy linkers, there might be a
kind of threshold for DOTA concerning labeling yield. At
0.6%, almost no labeling could be achieved whereas with
1.2%, high labeling yields were evident. Furthermore, the
structure of the linker has more influence on labeling yield
and stability than the linker length. That can be explained
as a possible unstable complexation of Ga(III) with the
oxygen present in the linker. Our hypothesis is that the
oxygens on the HPMA structure could induce a more ag-
gregated structure with alkoxy linkers compared to those
without oxygens, maybe by van der Waals interaction as it
was shown for other biopolymers [37], thus hindering the
DOTA availability for the metals. Furthermore, there is no
competition between the oxygens and the DOTA. More
likely, the van der Waals interactions slightly reduce the
complexation of DOTA with the metal.
The conjugate 31c was also labeled with scandium-44
and further analyzed in vivo because of the minimal al-
terations to structure and geometry and very good radio-
chemical purity and stability. The polymer shows a fast
renal clearance in vivo.
These findings of the in vivo measured tracer kinetics
are in line with earlier data on low molecular weight
HPMA homopolymers, which were labeled with fluorine-
18 and showed comparable pharmacokinetics after 2 h
[20]. By labeling with the longer-lived scandium-44, im-
aging time could be prolonged which favors imaging of
slower molecular processes like the accumulation of tar-
geted drugs into tumors or the activation of T cells after a
special vaccination.
HPMA-copolymer conjugates have been successfully
utilized in the delivery of miscellaneous drugs (e.g.,
doxorubicin [14], paclitaxel [15], camptothecin [16]).
Modification can be achieved through activated co-
monomers leading to biocompatible polymers with func-
tionalities for polymer-analogue reaction. This strategy is
very flexible in the choice of ligands, type of activation,
and occupancy rate and was already used in various
studies [17]. Reaction of a reactive ester polymer with
several ligands leads to multifunctionalized copolymers
which can be applied for theranostic applications. Re-
cently, a synthetic pathway was shown that combines con-
trolled radical polymerization with post-polymerization
modification of a perfluorinated reactive ester [38] to get
access to well-defined HPMA-based block copolymers of
low dispersity and controlled copolymer structure with a
high degree of multiple functionalities. With this technol-
ogy, advanced HPMA-based polymer conjugates and
nano-sized self-assemblies could be developed that may
serve as novel drug carriers. Moreover, the high degree of
functionalities enables novel applications for HPMA-
based copolymers, for instance, in the field of tumor im-
munotherapy [39].
Interestingly, despite the low molecular weight, with-
out any expected EPR effect, tumor accumulation
slightly increased over time while tracer concentration
in the blood decreased. The enhanced tumor accumula-
tion could be due to the higher permeability reported
for B16F10 tumors compared to any other tumor types
[40]. However, this 24-h blood value is also well compar-
able to earlier data by Lammers et al. [41] were they la-
beled HPMA copolymers of different weights by
iodination (iodine-131) and discovered the body distri-
bution up to 168 h p.i. [41]. Here, the smallest evaluated
polymer (23 kDa) showed a similar blood retention after
24 h like the HPMA polymer in our study even though
those studies were performed in rats and with another
tumor model.
Interestingly, our findings on the different blood com-
ponents suggested that the homopolymer interacts with
serum proteins and with blood cells. Former studies of
our group showed that HPMA-ran-LMA copolymers
interact with very low density lipoproteins in the blood
[42] and with cell membranes [43, 44]. Not only struc-
ture and size of the polymer but furthermore the cell
type is crucial for polymer delivery. Moreover, hydro-
philic homopolymers (like in our case) were taken up by
micropinocytosis as well as by clathrin-mediated and
clathrin-independent endocytosis [45].
Furthermore, it is well known that nanoparticles and
polymers are opsonized by plasma proteins upon enter-
ing the blood stream [46, 47] which alters their molecu-
lar size, charge, and aggregation behavior and thereby
their physicochemical properties dramatically. One could
imagine that the HPMA polymers used in this study get
“sticky” by the protein corona and may bind unspecifi-
cally to cells in the blood stream (monocytes, granulo-
cytes, B and T cells) or may even be endocytosed.
Especially, when polymers are opsonized by complement
factors, which were also identified in the protein corona
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of nanocarriers [48, 49], they will be taken up rapidly by
circulating cells of the immune system. Several in vitro
studies showed that dendritic cells can bind and take up
HPMA-based homopolymers [39, 50] and even other
immune cells like granulocytes and B and T cells do so.
To our knowledge, our study is the first proof of
principle study that analyzes the labeling of HMPA poly-
mers with scandium-44 and its in vivo distribution. Be-
sides high in vitro stabilities, the good in vivo stability
enables imaging of biological processes for up to 24 h.
Further studies will focus on the comparison of different
molecular weight polymers for enhanced EPR-mediated
enrichment into tumors as well as receptor-mediated
targeting to tumors as it was shown for [44Sc]Sc-DOTA-
NAPamide for melanoma imaging [51].
Conclusions
This study confirms the principle applicability of HPMA
conjugates for labeling with different metallic radionu-
clides with established radiolabeling chemistry. Introdu-
cing as less than only 1.6% of DOTA chelator using a
short linker chain, which facilitates the synthesis and ef-
ficiency of the polymer conjugates, allows introduction
of both diagnostic and therapeutic radiometals. The
introduction of [44Sc]Sc-DOTA as well as lutetium-177
into HPMA polymers allows for longer observation
times than for example 18F-labeling being a good pre-
requisite for tumor imaging and therapy in the future.
Additional file
Additional file 1: Supporting information. (ZIP 77 kb)
Abbreviations
DOTA: 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid;
DTPA: Diethylenetriaminepentaacetic acid; EDTA: Ethylenediaminetetraacetic
acid; EPR: Enhanced permeability and retention; GPC: Gel permeation
chromatography; HPMA: N-(2-Hydroxypropyl)methacrylamide; HSA: Human
serum albumin; NaCl: Sodium chloride; NMR: Nuclear magnetic resonance;
PDI: Polydispersity index; PET: Positron emission tomography;
THF: Tetrahydrofuran; TLC: Thin-layer chromatography
Acknowledgements
The authors would like to thank Nicole Bausbacher for her support during
the animal studies.
Funding
E. Eppard has been funded by the Dr. Georg-Scheuing Stiftung. A. de la
Fuente has been funded by the People Programme (Marie Curie Actions) of
the European Union’s Seventh Framework Programme (FP7/2007–2013)
under REA grant agreement no. PITN-GA-2012-317019 “Trace ‘n Treat”. All
other authors have been funded by the DFG (SFB1066).
Availability of data and materials
The datasets supporting the conclusions of this article are included within
the article (and in Additional file 1).
Authors’ contributions
EE and AdlF performed the experiments, analyzed the data, and wrote the
manuscript. MA and NM performed the experiments and analyzed the data.
SP designed and performed the animal studies, analyzed the data, and
wrote the manuscript. MM, RZ, and FR designed the study and wrote the
manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
All experiments were performed in accordance with federal guidelines and
approved by the ethical committee of the state of Rhineland-Palatinate
(according to §8 Abs. 1 Protection of Animals Act, Regional Investigational
Authority Institute/Office Landesuntersuchungsamt; permission no. 23177-07/
G12-1-092 to M. Miederer).
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Clinic for Nuclear Medicine, University Medical Center Bonn, Bonn, Germany.
2Institute of Nuclear Chemistry, Johannes Gutenberg University Mainz, Mainz,
Germany. 3Institute of Organic Chemistry, Johannes Gutenberg University
Mainz, Mainz, Germany. 4Clinic for Nuclear Medicine, University Medical
Center Mainz, Langenbeckstraße 1, 55131 Mainz, Germany.
Received: 8 December 2017 Accepted: 19 February 2018
References
1. Arranja AG, Pathak V, Lammers T, Shi Y. Tumor-targeted nanomedicines for
cancer theranostics. Pharmacol Res. 2017;115:87–95.
2. Landesman-Milo D, Peer D. Transforming nanomedicines from lab scale
production to novel clinical modality. Bioconjug Chem. 2016;27(4):855–62.
3. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and
retention effect for tumor targeting. Drug Discov Today. 2006;11(17–18):812–8.
4. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug
delivery to solid tumors: improvement of tumor uptake, lowering of
systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev.
2013;65(1):71–9.
5. Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, Akaike T, et al. Early
phase tumor accumulation of macromolecules: a great difference in
clearance rate between tumor and normal tissues. Jpn J Cancer Res. 1998;
89(3):307–14.
6. Kopeček J, Baẑilová H. Poly[N-(2-hydroxypropyl)methacrylamide]—I. Radical
polymerization and copolymerization. Eur Polym J. 1973;9(1):7–14.
7. Bohdanecky M, Baẑilová H, Kopeček J. Poly[N-(2-
hydroxypropyl)methacrylamide]—II: hydrodynamic properties of dilute
solutions. Eur Polym J. 1974;10(5):405–10.
8. Kopecek J, Sprincl L. Relationship between the structure and
biocompatibility of hydrophilic gels. Polim Med. 1974;4(2):109–17.
9. Kopecek J, Sprincl L, Bazilova H, Vacik J. Biological tolerance of poly(N-
substituted acrylamides). J Biomed Mater Res. 1973;7(1):111–21.
10. Kopecek J, Sprincl L, Lim D. New types of synthetic infusion solutions. I.
Investigation of the effect of solutions of some hydrophilic polymers on
blood. J Biomed Mater Res. 1973;7(2):179–91.
11. Sprincl L, Kopecek J, Lim D. Effect of porosity of heterogeneous poly(glycol
monomethacrylate) gels on the healing-in of test implants. J Biomed Mater
Res. 1971;5(5):447–58.
12. Sprincl L, Vacik J, Kopecek J. Biological tolerance of ionogenic hydrophilic
gels. J Biomed Mater Res. 1973;7(1):123–36.
13. Ulbrich K, Sprincl L, Kopecek J. Biocompatibility of poly (2,4-pentadiene-1-
ol). J Biomed Mater Res. 1974;8(2):155–61.
14. Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, et al. Phase I
clinical and pharmacokinetic study of PK1 [N-(2-
hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a
new class of chemotherapeutic agents-drug-polymer conjugates. Cancer
Research Campaign Phase I/II Committee. Clin Cancer Res. 1999;5(1):83–94.
Eppard et al. EJNMMI Research  (2018) 8:16 Page 13 of 14
15. Meerum Terwogt JM, ten Bokkel Huinink WW, Schellens JH, Schot M,
Mandjes IA, Zurlo MG, et al. Phase I clinical and pharmacokinetic study of
PNU166945, a novel water-soluble polymer-conjugated prodrug of
paclitaxel. Anti-Cancer Drugs. 2001;12(4):315–23.
16. Schoemaker NE, van Kesteren C, Rosing H, Jansen S, Swart M, Lieverst J, et
al. A phase I and pharmacokinetic study of MAG-CPT, a water-soluble
polymer conjugate of camptothecin. Br J Cancer. 2002;87(6):608–14.
17. Kopecek J, Kopeckova P, Minko T, Lu Z. HPMA copolymer-anticancer drug
conjugates: design, activity, and mechanism of action. Eur J Pharm
Biopharm. 2000;50(1):61–81.
18. Sprincl L, Kopecek J, Vacik J, Lim D. Biological tolerance of poly(N-
substituted methacrylamides). J Biomed Mater Res. 1971;5(3):197–205.
19. Chidambaram M, Manavalan R, Kathiresan K. Nanotherapeutics to overcome
conventional cancer chemotherapy limitations. J Pharm Pharm Sci. 2011;
14(1):67–77.
20. Allmeroth M, Moderegger D, Biesalski B, Koynov K, Rosch F, Thews O, et al.
Modifying the body distribution of HPMA-based copolymers by molecular
weight and aggregate formation. Biomacromolecules. 2011;12(7):2841–9.
21. Allmeroth M, Moderegger D, Gundel D, Buchholz HG, Mohr N, Koynov K, et
al. PEGylation of HPMA-based block copolymers enhances tumor
accumulation in vivo: a quantitative study using radiolabeling and positron
emission tomography. J Control Release. 2013;172(1):77–85.
22. Breeman WA, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning
EP. Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging.
2005;32(4):478–85.
23. Mueller D, Klette I, Baum RP, Gottschaldt M, Schultz MK, Breeman WA.
Simplified NaCl based (68)Ga concentration and labeling procedure for
rapid synthesis of (68)Ga radiopharmaceuticals in high radiochemical purity.
Bioconjug Chem. 2012;23(8):1712–7.
24. Meyer GJ, Macke H, Schuhmacher J, Knapp WH, Hofmann M. 68Ga-labelled
DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging. 2004;31(8):
1097–104.
25. Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, et al.
Processing of generator-produced 68Ga for medical application. J Nucl
Med. 2007;48(10):1741–8.
26. Eppard E, Wuttke M, Nicodemus PL, Rosch F. Ethanol-based post-processing
of generator-derived (6)(8)Ga toward kit-type preparation of (6)(8)Ga-
radiopharmaceuticals. J Nucl Med. 2014;55(6):1023–8.
27. Rosch F, Baum RP. Generator-based PET radiopharmaceuticals for molecular
imaging of tumours: on the way to THERANOSTICS. Dalton Trans. 2011;
40(23):6104–11.
28. Filosofov DV, Loktionova NS, Rösch F. A 44Ti/44Sc radionuclide generator
for potential application of 44Sc-based PET-radiopharmaceuticals.
Radiochimica Acta Int J Chem Aspects Nucl Sci Technol. 2010;98:149–56.
29. Pruszynski M, Loktionova NS, Filosofov DV, Rosch F. Post-elution processing
of (44)Ti/(44)Sc generator-derived (44)Sc for clinical application. Appl Radiat
Isot. 2010;68(9):1636–41.
30. Liu Z, Ma T, Liu H, Jin Z, Sun X, Zhao H, et al. 177Lu-labeled antibodies for
EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical
head and neck carcinoma model. Mol Pharm. 2014;11(3):800–7.
31. Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, et
al. Hepatic drug targeting: phase I evaluation of polymer-bound
doxorubicin. J Clin Oncol. 2002;20(6):1668–76.
32. Mitra A, Nan A, Ghandehari H, McNeill E, Mulholland J, Line BR. Technetium-
99m-labeled N-(2-hydroxypropyl) methacrylamide copolymers: synthesis,
characterization, and in vivo biodistribution. Pharm Res. 2004;21(7):1153–9.
33. Benezra M, Penate-Medina O, Zanzonico PB, Schaer D, Ow H, Burns A, et al.
Multimodal silica nanoparticles are effective cancer-targeted probes in a
model of human melanoma. J Clin Invest. 2011;121(7):2768–80.
34. Mohr N, Barz M, Forst R, Zentel R. A deeper insight into the
postpolymerization modification of polypenta fluorophenyl methacrylates
to poly(n-(2-hydroxypropyl) methacrylamide). Macromol Rapid Commun.
2014;35(17):1522–7.
35. Pruszynski M, Majkowska-Pilip A, Loktionova NS, Eppard E, Roesch F.
Radiolabeling of DOTATOC with the long-lived positron emitter 44Sc. Appl
Radiat Isot. 2012;70(6):974–9.
36. Roesch F, Perez-Malo CM. Improved efficacy of synthesis of 68Ga
radiopharmaceuticals in mixtures of aqueous solution and non-aqueous
solvents. J Nucl Med. 2013;54(supplement 2):163.
37. Van Oss CJ, Good RJ, Chaudhury MK. The role of van der Waals forces and
hydrogen bonds in “hydrophobic interactions” between biopolymers and
low energy surfaces. J Colloid Interface Sci. 1986;111(2):378–90.
38. Nuhn L, Barz M, Zentel R. New perspectives of HPMA-based copolymers
derived by post-polymerization modification. Macromol Biosci. 2014;14(5):
607–18.
39. Mohr N, Kappel C, Kramer S, Bros M, Grabbe S, Zentel R. Targeting cells of
the immune system: mannosylated HPMA-LMA block-copolymer micelles
for targeting of dendritic cells. Nanomedicine (London, England). 2016;
11(20):2679–97.
40. Mei KC, Bai J, Lorrio S, Wang JT, Al-Jamal KT. Investigating the effect of
tumor vascularization on magnetic targeting in vivo using retrospective
design of experiment. Biomaterials. 2016;106:276–85.
41. Lammers T, Kuhnlein R, Kissel M, Subr V, Etrych T, Pola R, et al. Effect of
physicochemical modification on the biodistribution and tumor
accumulation of HPMA copolymers. J Control Release. 2005;110(1):103–18.
42. Hemmelmann M, Mohr K, Fischer K, Zentel R, Schmidt M. Interaction of
pHPMA-pLMA copolymers with human blood serum and its components.
Mol Pharm. 2013;10(10):3769–75.
43. Clemens-Hemmelmann M, Kuffner C, Metz V, Kircher L, Schmitt U, Hiemke
C, et al. Amphiphilic copolymers shuttle drugs across the blood-brain
barrier. Macromol Biosci. 2016;16(5):655–65.
44. Hemmelmann M, Metz VV, Koynov K, Blank K, Postina R, Zentel R.
Amphiphilic HPMA-LMA copolymers increase the transport of rhodamine
123 across a BBB model without harming its barrier integrity. J Control
Release. 2012;163(2):170–7.
45. Gundel D, Allmeroth M, Reime S, Zentel R, Thews O. Endocytotic uptake of
HPMA-based polymers by different cancer cells: impact of extracellular
acidosis and hypoxia. Int J Nanomedicine. 2017;12:5571–84.
46. Walczyk D, Bombelli FB, Monopoli MP, Lynch I, Dawson KA. What the cell
“sees” in bionanoscience. J Am Chem Soc. 2010;132(16):5761–8.
47. Tenzer S, Docter D, Kuharev J, Musyanovych A, Fetz V, Hecht R, et al. Rapid
formation of plasma protein corona critically affects nanoparticle
pathophysiology. Nat Nanotechnol. 2013;8(10):772–81.
48. Tenzer S, Docter D, Rosfa S, Wlodarski A, Kuharev J, Rekik A, et al.
Nanoparticle size is a critical physicochemical determinant of the human
blood plasma corona: a comprehensive quantitative proteomic analysis.
ACS Nano. 2011;5(9):7155–67.
49. Allemann E, Gravel P, Leroux JC, Balant L, Gurny R. Kinetics of blood
component adsorption on poly(D,L-lactic acid) nanoparticles: evidence of
complement C3 component involvement. J Biomed Mater Res. 1997;37(2):
229–34.
50. Tappertzhofen K, Bednarczyk M, Koynov K, Bros M, Grabbe S, Zentel R.
Toward anticancer Immunotherapeutics: well-defined polymer-antibody
conjugates for selective dendritic cell targeting. Macromol Biosci. 2014;
14(10):1444–57.
51. Nagy G, Denes N, Kis A, Szabo JP, Berenyi E, Garai I, et al. Preclinical evaluation
of melanocortin-1 receptor (MC1-R) specific 68Ga- and 44Sc-labeled DOTA-
NAPamide in melanoma imaging. Eur J Pharm Sci. 2017;106:336–44.
Eppard et al. EJNMMI Research  (2018) 8:16 Page 14 of 14
